A Study to Learn How Different Formulations of Study Medication Tafamidis are Taken Up into the Blood in Healthy Adults
A Phase 1, Open-Label, Randomized, Three-Treatment, Three-Period, Crossover, Single Dose Study to Estimate the Relative Bioavailability of 61 mg and 70 mg Tafamidis Free Acid Tablets to Commercial 61 mg Tafamidis Free Acid Capsule Administered Under Fasted Conditions in Healthy Adult Participants
Category & Conditions: Cardiovasular Diseases and Conditions
Medicine: VYNDAQEL® (TAFAMIDIS MEGLUMINE)
ClinicalTrials.gov Identifier (NCT): NCT06273839
Protocol ID: B3461114
Report Type: Final
Language: English
Open Plain Language Summary Result:
Click here